Literature DB >> 7788168

Antibodies to Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis in the sera of patients with axial and peripheral form of ankylosing spondylitis.

O Mäki-Ikola1, M Nissilä, K Lehtinen, M Leirisalo-Repo, P Toivanen, K Granfors.   

Abstract

IgM, IgG and IgA class serum antibodies against the whole Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis bacteria, as well as against K. pneumoniae and E. coli lipopolysaccharides (LPSs) were studied earlier in two separate patient populations of 99 and 85 patients with ankylosing spondylitis (AS) and in 102 healthy blood donors by enzyme immunoassay. In this study the patients were divided into groups according to the presence or absence of peripheral arthritis. The patients with peripheral type AS had increased levels of IgM and IgA class antibodies against K. pneumoniae, whereas the patients with axial type AS had increased levels of IgG and IgA class antibodies to K. pneumoniae, as well as IgA class antibodies against E. coli and P. mirabilis bacteria. Sulphasalazine treatment decreased the IgM and IgA class antibodies in peripheral AS and IgA class antibodies in axial AS against K. pneumoniae LPS. The antibody levels were also decreased against E. coli and P. mirabilis bacteria in the sera of patients with axial AS. The immunological findings in patients with peripheral and axial form of AS were different from each other and thus may reflect different aetiopathogenetic mechanisms for these two types of AS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7788168     DOI: 10.1093/rheumatology/34.5.413

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  7 in total

1.  The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms.

Authors:  Jane Zochling; Martin H J Bohl-Bühler; Xenofon Baraliakos; Ernst Feldtkeller; Jürgen Braun
Journal:  Clin Rheumatol       Date:  2005-12-23       Impact factor: 2.980

Review 2.  HLA-B27 and bacteria.

Authors:  J Uksila; P Toivanen
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

3.  A complex role of anthrax toxin receptor 2 polymorphisms and capillary morphogenesis protein 2 in ankylosing spondylitis pathogenesis.

Authors:  Zhijian Zhang; Kun Yu; Dongfa Dai; Fang Yuan; Fei Liang; Nan Liu; Yongzhi Xi; Yu-Ying Sun
Journal:  Clin Rheumatol       Date:  2016-01-04       Impact factor: 2.980

4.  Ankylosing spondylitis in monozygotic twins: studies on immunological parameters.

Authors:  T Höhler; R Hug; P M Schneider; F Krummenauer; C Gripenberg-Lerche; K Granfors; E Märker-Hermann
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

Review 5.  Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis.

Authors:  Tony J Kenna; Aimee Hanson; Mary-Ellen Costello; Matthew A Brown
Journal:  Curr Rheumatol Rep       Date:  2016-10       Impact factor: 4.592

Review 6.  Juvenile onset spondyloarthropathies: therapeutic aspects.

Authors:  R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

7.  Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic Escherichia coli (DEC).

Authors:  Riitta Tuompo; Tinja Lääveri; Timo Hannu; Sari H Pakkanen; Juha Kirveskari; Marjatta Leirisalo-Repo; Anu Kantele
Journal:  Ann Rheum Dis       Date:  2020-03-16       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.